Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 09-03 15:00:00

22.28

+0.08

+0.36%

High22.35	Low22.11	Vol12.45M
Open22.21	D1 Closing22.20	Amplitude1.08%
Mkt Cap59.49B	Tradable Cap47.19B	Total Shares2.67B
T/O277.00M	T/O Rate0.59%	Tradable Shares2.12B
P/B1.22	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":22.28,"timestamp":1788418800000,"preClose":22.2,"halted":0,"volume":12446476,"delay":0,"changeRate":0.0036,"floatShares":2118000000,"shares":2670000000,"eps":1.2695,"marketStatus":"Closed","change":0.08,"latestTime":"09-03 15:00:00","open":22.21,"high":22.35,"low":22.11,"amount":277000000,"amplitude":0.0108,"askPrice":22.29,"askSize":341,"bidPrice":22.28,"bidSize":263,"shortable":0,"etf":0,"ttmEps":1.2695,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.2,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":24.42,"lowLimit":19.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.22,"roa":"--","peRate":17.550217,"roe":"3.53%","epsLYR":1.27,"committee":-0.254029,"marketValue":59497000000,"turnoverRate":0.0059,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":16.14,"timestamp":1788422901002,"preClose":15.83,"halted":0,"volume":3733000,"delay":0,"premium":"-37.92"},"floatMarketCap":47200000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2664789658","title":"Fosun Pharma Subsidiary Shanghai Fosun Pharmaceutical Industrial Development Wins China Approval for New Luvometinib Use in Adult NF1 Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664789658","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664789658?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:20","pubTimestamp":1788427217,"startTime":"0","endTime":"0","summary":"Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumorsShanghai Fosun Pharma unit Shanghai Fosun Pharmaceutical Ind","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1pp0pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0060","BK1230","BK0096","BK0183","00656","BK0012","BK0175","BK0187","BK0196","600196","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878952","title":"Shanghai Fosun Pharma - Drug Registration Application for Additional Indication of Luvometinib Tablets of Unit Approved by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878952?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:20","pubTimestamp":1788427213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0196","BK1191","02196","BK0012","BK0187","BK1593","BK0028","BK0183","600196","BK0175","BK0239","BK0188","BK1515","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168391109","title":"Shanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1168391109","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168391109?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:26","pubTimestamp":1788423987,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK1515","BK0096","BK0183","BK0188","BK0028","600196","BK0060","BK1191","BK0187","BK0239","BK0012","02196","BK1593","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664185964","title":"Regent Pacific Gets $4.5 Million Milestone Payment from Fosun Pharma Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2664185964","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664185964?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:23","pubTimestamp":1788265421,"startTime":"0","endTime":"0","summary":"Regent Pacific  received a milestone payment of $4.5 million from Fosun Wanbang  Pharmaceutical Group on Monday.The payment was received under a licence and collaboration arrangement related to Senstend between the parties, according to a Tuesday bourse filing.Fosun Wanbang  Pharmaceutical Group is expected to begin the commercialization of Senstend in China, leading to further milestone and royalty payments to the company.Fosun Wanbang  Pharmaceutical Group is a unit of Shanghai Fosun Pharmaceutical .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0187","00575","BK1515","BK0175","BK0028","BK0188","BK1593","BK1191","BK0096","BK0012","BK0060","600196","BK0196","BK0183","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128973131","title":"Fosun Pharma Spends HK$4.28 Million on Share Buyback on September 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1128973131","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128973131?lang=en_us&edition=fundamental","pubTime":"2026-09-01 17:28","pubTimestamp":1788254894,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that on September 1, 2026, it repurchased 264,000 shares for a total consideration of HK$4.278 million, at a price range of HK$16.07 to HK$16.28 per share.The repurchase reflects the company's ongoing capital management strategy amid market conditions.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0012","BK0060","BK0183","BK0188","BK0196","BK0096","BK0175","BK1515","BK0239","02196","BK1593","600196","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079491","title":"Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing H-Share Buyback at HKD 16.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079491","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079491?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:43","pubTimestamp":1788169381,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharma files HKEX next-day return disclosing H-share buyback at HKD 16.03Shanghai Fosun Pharmaceutical repurchased 70,500 H shares on Aug. 31, holding them as treasury shares; no shares","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLb0ZmkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0183","BK0060","BK1230","BK0188","BK0175","BK0196","BK0096","BK0239","BK0012","BK0028","00656","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184432934","title":"Fosun Pharma Allocates 725,100 A-Share Options to Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=1184432934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184432934?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:00","pubTimestamp":1787914813,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) has announced a new round of equity incentives, granting a total of 725,100 A-share options to 100 eligible recipients.According to the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK1191","BK1515","82846","03188","02827","07233","BK0096","BK0239","83130","BK1147","02846","159982","600196","BK0175","BK0012","BK0028","BK0183","02196","03130","BK1593","BK0188","BK0060","BK0196","83188","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056779","title":"Shanghai Fosun Pharmaceutical's GR1803 Injection Gets Conditional Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056779","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662056779?lang=en_us&edition=fundamental","pubTime":"2026-08-28 13:20","pubTimestamp":1787894451,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  GR1803 injection received conditional approval from China's National Medical Products Administration as a multiple myeloma treatment, according to a Friday disclosure on the Shanghai bourse.The drug, which has the generic name veritumab injection, is for adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of therapy, including a proteasome inhibitor and an anti-CD38 monoclonal antibody.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0028","BK0196","BK0012","BK0239","02196","600196","BK1191","BK1515","BK1593","BK0188","BK0175","BK0096","BK0187","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199001247","title":"Fosun Pharma Secures Conditional NMPA Approval for GR1803 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1199001247","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199001247?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:20","pubTimestamp":1787829620,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (H-share ticker: 02196) announced that its controlling subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd. (\"Yaoyou Pharma\"), has obtained...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK1593","BK0096","BK0239","02196","BK0060","BK0183","600196","BK0028","BK0188","BK0175","BK0196","BK0012","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662709438","title":"Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662709438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662709438?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:06","pubTimestamp":1787828777,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1191","BK1515","BK0175","BK1593","BK0028","BK0012","BK0060","BK0183","02196","BK0187","BK0096","BK0188","600196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132782268","title":"Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1132782268","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132782268?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:40","pubTimestamp":1787823619,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that on August 27, 2026, it repurchased 217,000 shares of its stock for a total consideration of HK$3.587 million.The buyback transaction reflects the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0096","BK0239","BK1191","BK1515","BK1593","BK0028","BK0188","BK0183","BK0060","02196","600196","BK0175","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662770477","title":"Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing H-Share Buyback at HKD 16.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2662770477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662770477?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:35","pubTimestamp":1787823302,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharma files HKEX next-day return disclosing H-share buyback at HKD 16.53Shanghai Fosun Pharmaceutical repurchased 217,000 H shares on Aug. 27, 2026 for HKD 3.59 million.Buyback price range HKD 16.45 to HKD 16.59 per share; weighted average HKD 16.53.All repurchased shares were held as treasury shares; cancelled shares: 0.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on August 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4T3cdj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","00656","BK0012","BK0096","BK0028","BK0188","BK0196","BK0239","BK0187","BK1230","600196","BK0060","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662964167","title":"Sinopharm Group Stock Rallies 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662964167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662964167?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:33","pubTimestamp":1787733180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 1.1% to 16.12 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 25652.97.The stock's rise snapped a two-day losing streak.Sinopharm Group Co. Ltd. closed 28% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 5.7%.Trading volume totaled 5.3 million shares, compared to the 50-day average of 5.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","BK0096","01099","BK0183","02196","LU0640798160.USD","BK0012","BK0239","BK0060","BK1191","BK1515","LU1115378108.SGD","SHTDY","BK0187","BK4175","BK1197","BK1593","BK0175","BK1500","BK0196","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171725498","title":"Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents","url":"https://stock-news.laohu8.com/highlight/detail?id=1171725498","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171725498?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:00","pubTimestamp":1787727650,"startTime":"0","endTime":"0","summary":"On August 25, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH; 02196.HK) unveiled its first-half scorecard. The interim results, disclosed on the evening of August 25, show operating...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0196","IBBQ","BK1593","BK1574","BK1191","BK0175","BK1161","BK0028","LNGR","BK0187","02196","BK0188","BK0239","600196","06978","BK0060","159992","BK0183","MEDX","BK1515","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662581763","title":"Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662581763","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662581763?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:06","pubTimestamp":1787702809,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  reported an attributable net profit of 1.72 billion yuan for the first half, up 1.15% from 1.70 billion yuan a year earlier.Earnings per share stood at 0.65 yuan, inching up from 0.64 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.Revenue increased 4.75% year over year to 20.4 billion yuan from 19.4 billion yuan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0096","BK0187","BK1593","BK0012","BK0060","BK0196","BK0239","FCA","02196","BK1191","BK0175","600196","BK0188","BK1515","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662573216","title":"Fosun Pharma 1H FY26 Profit Attributable to Shareholders Rises 19.09% to RMB 1.14 Billion; Revenue Increases 4.75% to RMB 20.44 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662573216","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662573216?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:45","pubTimestamp":1787661946,"startTime":"0","endTime":"0","summary":"Fosun Pharma 1H FY26 profit attributable to shareholders rises 19.09% to RMB 1.14 billion; revenue increases 4.75% to RMB 20.44 billionFosun Pharma posted 1H2026 revenue of RMB 20.44 billion, up 4.75%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL9zCfX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0060","BK0183","00656","BK0188","BK0196","BK0096","BK0175","BK1230","BK0239","600196","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662322847","title":"Press Release: Fosun Pharma Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662322847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662322847?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:44","pubTimestamp":1787661840,"startTime":"0","endTime":"0","summary":"Globalization Accelerates Value Realization of Innovative DrugsSHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma (\"the Company\", stock code: 600196.SH; 02196.HK) announced its interim","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0096","BK1191","BK1515","BK0028","BK0188","BK0060","600196","BK0187","BK0175","BK4232","BK0183","BK4022","BK0239","NVIB","R","BK0196","BK1593","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662170738","title":"Shanghai Fosun Pharmaceutical H1 Net Profit up 1.15% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662170738","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662170738?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:49","pubTimestamp":1787651372,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical H1 Net Profit Up 1.15% Y/YAug 25 (Reuters)-Shanghai Fosun Pharmaceutical Group Co Ltd600196.SS:H1 NET PROFIT UP 1.15% Y/YSource textFurther company coverage:600196.SS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL4N44M0KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0060","BK0187","BK0012","BK0183","BK0028","BK0196","BK0175","600196","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221432","title":"Sinopharm Group Stock Falls 1.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661221432?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:32","pubTimestamp":1787560320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. shed 1.9% to 16.33 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.Sinopharm Group Co. Ltd. closed 27% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.Despite its losses, the stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 3.3%.Trading volume totaled 5.3 million shares, compared to the 50-day average of 5.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0028","600196","LU1115378108.SGD","BK0060","BK0239","SHTDY","LU0640798160.USD","BK1500","BK0187","BK0183","BK1515","BK1191","01099","BK0175","BK1197","BK0196","BK0012","02196","BK4175","BK1593","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128694046","title":"Fosun Pharma Subsidiary Enters Collaboration Framework and License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1128694046","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128694046?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:04","pubTimestamp":1786925065,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that on August 16, 2026, its controlling subsidiary, Henlius, entered into a Collaboration Framework Agreement with Sandoz...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0196","BK1191","02196","BK0012","BK0187","BK1593","BK0028","BK0183","600196","BK0175","BK0239","BK0188","BK1515","BK0096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788463232460,"stockEarnings":[{"period":"1week","weight":-0.0266},{"period":"1month","weight":-0.0392},{"period":"3month","weight":0.0293},{"period":"6month","weight":-0.1252},{"period":"1year","weight":-0.2681},{"period":"ytd","weight":-0.1444}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是注射用曲妥珠单抗（中国境内商品名：汉曲优）及曲妥珠单抗原液、汉利康（利妥昔单抗注射液）、斯鲁利单抗注射液（中国境内商品名：汉斯状）、奥康泽(奈妥匹坦帕洛诺司琼胶囊)、奕凯达（阿基仑赛注射液）、一心坦（沙库巴曲缬沙坦钠片）、汉贝泰（贝伐珠单抗注射液）、汉奈佳（马来酸奈拉替尼片）、倍稳（盐酸凯普拉生片）、珮金（拓培非格司亭注射液）、苏可欣（马来酸阿伐曲泊帕片）、汉达远（阿达木单抗注射液）、普瑞尼（普托马尼片）、达希斐（注射用A型肉毒毒素）、复可舒（抗人T细胞兔免疫球蛋白）、复迈宁（芦沃美替尼片）、欧泰乐（阿普米司特片）、地舒单抗注射液、复妥宁（枸橼酸伏维西利胶囊）、汉倍优（帕妥珠单抗注射液）、万缇乐（盐酸替那帕诺片）、旁必福（盐酸依特卡肽注射液）。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction